can you take glp 1 if you had breast cancer The Impact and Safety of GLP‐1 Agents and Researchers from Penn Medicine found

Specifically, after 30 weeks, 36.7% of patients receiving exenatide twice-daily were antibody-positive

(PubMed) Wilson SM, Bivins BN, Russell KA, Bailey LB

Researchers found a duration dependent link between the use of GLP-1s and the cumulative 3-year risk of major adverse cardiovascular events: myocardial infarction, stroke, or all-cause death

In 2015, a landmark trial published the New England Journal of Medicine showed that a once daily subcutaneous injection of liraglutide produced a more than 10 per cent weight loss in a third of those living with obesity and without type 2 diabetes

Compounded Semaglutide Dosing Strategies to Minimize Balance Issues The PlexusDx Precision Peptide Genetic Test analyzes GLP1R, GIPR, FTO, and MC4R variants that relate to GLP-1 and related signaling pathways